Denali Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 22.42, 117.85, 427.03, 454.59, 811.01 ], "ebit_estimate": [ -548.76, -502.26, -290.14, -220.45, 112.4 ], "ebitda_estimate": [ -547.02, -504.77, -257.08, -50.6, 82.97 ], "net_income_estimate": [ -476.68, -466.39, -272.28, -202.2, 141.37 ], "per_share_eps_estimate": [ -2.45, -2.39, -1.06, -0.43, 1.16 ], "eps_nri_estimate": [ -2.46, -2.41, -0.97, -0.31, 1.39 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 3.3, 2.8, 2.92, 1.76, 3.41 ], "pretax_income_estimate": [ -478.81, -463.7, -209.9, -176.53, 169.21 ], "operating_cash_flow_per_share_estimate": [ -2, -1.67, -1.63, -0.12, 1.31 ], "roa_estimate": [ -52.9, -65.9, -49.6, -8.3, 27.5 ], "roe_estimate": [ -64.74, -89.68, -81.09, -16.4, 44.3 ], "gross_margin_estimate": [ 47.63, 82.95, 84.63, 88.43, 87.8 ], "operating_cash_flow_estimate": [ -372.66, -312.3, -303.29, -22.4, 244.49 ], "pettm_estimate": [ 0, 0, 0, 0, 22.08 ], "long_term_growth_rate_mean": 28.63, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 26.83, "future_eps_nri_estimate_growth": 28.63, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 18.42, "future_ebitda_estimate_growth": 20.62, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 17.46, "future_pretax_income_estimate_growth": 23.74, "future_book_value_per_share_estimate_growth": -22.6, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -22.72, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 12.49 }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712", "202803" ], "revenue_estimate": [ 15.42, 3.68, 13.3, 14.3, 21.29, 29.69, 39.4, 125.19 ], "ebit_estimate": [ -142.27, -134.67, -134.08, -144.16, -143.08, -142.27, -139.43, null ], "ebitda_estimate": [ -137.55, -140.6, -139.83, -142.85, null, null, null, null ], "net_income_estimate": [ -118, -111.87, -125.07, -130.99, -131.25, -130.98, -103.5, null ], "per_share_eps_estimate": [ -0.65, -0.6, -0.66, -0.66, -0.65, -0.57, -0.45, -0.25 ], "eps_nri_estimate": [ -0.66, -0.55, -0.67, -0.68, -0.65, -0.58, -0.49, -0.25 ], "dividend_estimate": [ null, null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null, null ], "pretax_income_estimate": [ -118, -108.54, -123.64, -130.99, -131.25, -130.98, -103.5, null ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null, null ], "gross_margin_estimate": [ 93, 93.17, 91.41, 80, 80, 80, 80, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": 28.63, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": 26.83, "future_eps_nri_estimate_growth": 28.63, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": 18.42, "future_ebitda_estimate_growth": 20.62, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": 17.46, "future_pretax_income_estimate_growth": 23.74, "future_book_value_per_share_estimate_growth": -22.6, "future_roa_estimate_growth": null, "future_roe_estimate_growth": -22.72, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": 12.49 }